Introduction
Autologous hematopoietic stem cell transplantation (HSCT), consisting of high dose chemotherapy and subsequent infusion of hematopoietic stem cells (CD34+cells) is a therapeutic procedure used in many hematologic malignancies.
Following HSCT a complex immune reconstitution (IR) is observed. When the infused CD34+cells (CD34+i) begin to proliferate, an increase in peripheral blood cells is detected. Lymphocytes require more time than granulocytes in order to reestablish their normal function during the early post-transplant period [1] .
An absolute lymphocyte count (ALC) 4500/μl at day 15 post-HSCT has been associated with a better prognosis in patients with hematologic malignancies [2] [3] [4] . Moreover, the number of CD34+i has been associated with ALC and clinical evolution. Hence, an ALC≤500/μl on day 15 has been proposed as an independent risk factor [3] [4] [5] [6] .
Our aim was to determine the influence of ALC, at day 15, in predicting post-HSCT outcome in patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma (MM) in terms of progression-free survival (PFS) and overall survival (OS), and to analyze the relationship between the number of CD34+i and the number of days required in order to reach ALC≥500/μl as well as clinical evolution.
Materials and methods

Patients and samples
Medical records of a total of 163 patients with hematologic malignancies receiving autologous-HSCT between January 2005 and March 2012 in our Hospital were reviewed. Patients with incomplete follow-up data and/or absent blood count at day 15 were excluded (n ¼7).
Autologous CD34+i during HSCT were obtained after bone marrow mobilization through administration of granulocytecolony stimulating factor (G-CSF) with or without concomitant chemotherapy. Collection of CD34+cells were performed using a blood cell separator (CS-3000 Plus, Baxter s ). Flow cytometry (FACScan, Becton Dickinson s ) and CD34+ count guides (ISHAGE)
were followed. A retrospective database was created, along with daily peripheral lymphocyte recounts until an ALC4 500/μl was obtained. Total number of days for endpoint (ALC4 500/μl) along with ALC at day 15 was determined.
Statistical methods
Patients were distributed into two groups depending on ALC (4or o500/μL) at day 15 post-HSCT. Correlation between CD34+i and time to ALC≥500/μ was analyzed using Spearman's correlation coefficient (r) and ANOVA test. OS and PFS were calculated according to the Kaplan-Meier curves and compared by log-rank OS and PFS were calculated from infusion day until death/end of follow-up, and disease relapse or progression respectively. Median follow-up of the study was 134 weeks (range: 69-294).
Statistical significance was established with a p value o0.05. SPSS (version 12/15) was used.
Results
Patient characteristics are detailed in Table 1 .
Patients with ALC4500/μl, n ¼ 94 (59.5%) had a higher PFS and OS compared with those with ALC below the limit, n ¼64 (40.5%): PFS 67 months (CI95%: 60. /Kg (range: 0.54-26.23) and the median of days required for an ALC≥500/μl was 14 (range: 3-30). We found a significant and inversely proportional relationship between the number of CD34+i and the days required to reach ALC ≥500/ml in patients with NHL (r¼ −0.625; p o0.001), HL (r¼ −0.801; po0.001) and MM (r¼ −0.662; po0.001) according to regression line (Fig. 2) Univariate analysis showed a statistically significant association between ALC at day 15 and prognosis, with higher OS and PFS in patients attaining ALC4500/μl. On the other hand, patients with CD34+i≥2.0 Â 10 6 /Kg showed a superior outcome, independent of the lymphocyte count and a protective effect on progression with an increase in PFS but no statistically significant relationship between CD34+i and OS. As expected, previous disease state seemed to have prognostic influence, with patients experiencing disease progression presenting with a worse OS and PFS than those in CR1 pre-HSCT. No significant differences on survival between patients in CR2 and those in PR were observed. In our experience, no significant correlation was found between the number of lines of therapy pre-HSCT and CD34 cell counts or lymphocyte recovery.
Multivariate analysis for ALC, CD34+i, disease state, age and sex showed that not reaching an ALC4500 at day 15 post-HSCT was an adverse factor for PFS with HR¼ 7.72 (CI95%: 4.05-14.7), po0.001 and for OS with HR¼ 9.7 (CI95%: 3.1-30.34), po0.001. In this series, we additionally observed that infusing ≥4.38 CD34+ Â 10 6 /Kg was associated with better survival in all groups, p¼0.015 and HR¼0.27 (CI95%: 0.094-0.774). Additionally, disease progression was found to be a statistically significant risk factor when compared to patients on CR1 pre-HSCT with HR¼4.28 (CI95%: 1.39-13.2), p¼0.011 but no significant differences were detected between patients with PR or CR2 with respect to those achieving CR1 with HR¼1.59(CI95%: 0.53-4.75), p¼0.400 and HR¼1.03 (CI95%: 0.30-3.52), p¼ 0.100, respectively. No statistically significant differences could be found between age or sex and ALC at day 15 with HR¼ 1.01 (CI95%: 0.99-1.04), p¼0.200 and HR¼1.76 (CI95%: 0.76-4.05), p¼ 0.180, respectively.
Discussion
In accordance with the results, we have been able to determine the existence of several factors with an impact on outcome after autologous HSCT. Additional variables have been reported [5] [6] [7] but detailed description of every single prognostic factor apparently involved in post-transplant evolution was beyond the scope of this study.
In accord with other authors [3] [4] [5] [6] [7] , patients in our study with localized disease at diagnosis showed better outcome compared to those whose disease was in an advanced stage. Furthermore, patients in CR1 or CR2 pre-HSCT showed better survival rates than those who presented with disease progression. Nevertheless, in contrast with other authors [6, 7] , there did not seem to be any significant difference in prognosis between patients in PR and those who achieved CR2 pre-HSCT.
Porrata et al. were the first to describe prognostic significance of early ALC in patients with HM undergoing HSCT [2] [3] [4] [5] and we confirmed that. Some authors have attributed this improvement in survival to a decrease in infection susceptibility in the subgroup of patients who managed to attain an early lymphocytic reconstitution (ELR) after HSCT [1, 2] . Even though we did not specifically analyze infection risk in our patients, we proposed that such a relation can be responsible for this observation.
Developing a means to predict ELR (to express as ALC) after HSCT could be of great use during transplantation. In order to try to prove this point, we obtained a predictive model capable of estimating total days for ELR according to CD34+i at day 0. Late ALC (after day 15) can probably be associated with a greater incidence of infections due to impaired immunity and, hence, a worse prognosis [6] [7] [8] . Consequently, pre-transplant knowledge of lymphocyte reconstitution dynamics should be able to define which subgroup of patients could benefit from early antibiotic therapy, and which optimal CD34+i count should be reached in order to guaranty ELR. In this sense, we propose early ALC as a predictive prognostic marker. Additionally, we found a positive correlation between CD34+i and dynamics of lymphocyte recovery, especially in patients with HL.
We have obtained a regression line as a predictive model of lymphocyte recovery, not previously described, based on CD34+i and it could be used as a prognosis tool in this patients. Nonetheless, future prospective studies analyzing lymphocyte subpopulations are needed to achieve a better understanding of IR. There are still many questions that remained unanswered.
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